Eur Rev Med Pharmacol Sci 2022; 26 (3): 1042-1048
DOI: 10.26355/eurrev_202202_28014

Evaluation of olfactory dysfunction persistence after COVID-19: a prospective study

M.R. Bianco, M. Ralli, A. Minni, A. Greco, M. de Vincentiis, E. Allegra

Otolaryngology Unit, Department of Health Science, University of Catanzaro, Catanzaro, Italy. massimo.ralli@uniroma1.it


OBJECTIVE: Alterations of the olfactory function in patients affected by COVID-19 often have an early onset and a variable duration ranging from a few weeks to months. The aim of this study was to evaluate olfactory dysfunction persistence after recovery from COVID-19, and potential related clinical-demographic conditions.

PATIENTS AND METHODS: A total of 76 patients recovered from COVID-19 from at least 20 days with olfactory dysfunction during the infection were included in the study. For the subjective evaluation of olfactory function, a visual analogic scale (VAS) was used. The objective evaluation was performed with the use of the Sniffin’ Sticks test.

RESULTS: Objective assessment of olfactory function revealed that 48 (63.16%) patients were found to be normosmic (TDI ≥ 30.5), 26 (34.21%) were hyposmic (TDI from 30.5 to 16.5) and two (2.63%) were anosmic (TDI ≤ 16.5) at the time of the evaluation. These results did not show a significant difference between subjective and objective tests (p = 0.45). Most patients recovered their sense of smell within the first two months after recovery while a portion (22.2%) still experienced olfactory alterations 4-6 months after SARS-CoV-2 infection. Patients who had not recovered their sense of smell had a significantly longer period of SARS-CoV-2 positivity compared to patients that fully recovered (36.07 ± 7.78 days vs. 29 ± 7.89 days; p = 0.04).

CONCLUSIONS: Our results suggest that the duration of the infection negatively correlates with the recovery of olfactory function.

Free PDF Download

To cite this article

M.R. Bianco, M. Ralli, A. Minni, A. Greco, M. de Vincentiis, E. Allegra
Evaluation of olfactory dysfunction persistence after COVID-19: a prospective study

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 3
Pages: 1042-1048
DOI: 10.26355/eurrev_202202_28014